Industry News

ISPOR Is Looking For Nominations For Board Of Directors

What If You Only Had To Pay For A Medication If It Worked?

A New Market Access Modus Operandi For US Pharma – Are You Ready?

Is The QALY A Valid Measurement?

Don’t Miss The Nation’s Largest Specialty Pharmacy Conference – Register Today!

A Quick Recap Of ISPOR’s HTA Asian Roundtable

If We Could Look Into The Future – What Would Healthcare Look Like?

Will The Majority Of Future Drugs Meet Orphan Drug Criteria?

Health Care Cost, Quality and Outcomes: ISPOR Book Of Terms

How To Construct Reimbursement Submissions In The Absence Of Head-To-Head Clinical Data

Valuable Insights From Germany’s AMNOG – Is It Working?

Abstract Submission For ISPOR 20th Annual International Meeting Now Open!

ISPOR’s Introduction To Health Systems Of BRICS Countries

Updated HTA Decision Map: How Are New Products Faring With Authorities In Europe, Canada and More

Therapeutic And Diagnostic Device Outcomes Research

Biosimilars – They’re Coming – Are You Ready?

How Can Digital Resources Help With Formulary Decision Making?

How Much Do You Know About The Pharmaceutical Markets In China & Hong Kong?

Evolving Health Systems In Asia: Opportunities And Challenges For Industry

Formulary Decision Makers Show Great Interest In Patient Support Tools

Barred Sales Reps, Disgraced Researchers & Groundbreaking New Apps – What Else Was In The News Last Week?

The Why, What, And How Of Big Data From ISPOR

ISPOR Taxonomy Of Patient Registries: Classification, Characteristics And Terms

Looking For Innovative Approaches For Achieving Value-Based, Quality Care In Oncology

Meet Sovaldi’s New Sidekick – Harvoni

Do Specialty Drugs Offer Reasonable Value For Money?

Breaking The Barriers Of Evidence-Based Medicine For A More Holistic Approach – Can It Be Done?

The Dangers Of Two-Tiered Generic Drug Plans

How Are Payers Controlling Costs With New Hepatitis C Treatments?

5 Ways To Not Suck At Power Point


Stay Connected